Curasight publishes information memorandum in connection with forthcoming rights issue
COPENHAGEN, Denmark, Feb. 22, 2024 /PRNewswire/ -- Curasight A/S ("Curasight" or the "Company") (XSAT: CURAS) has prepared and published an information memorandum (the "Information Memorandum") relating to the new issue of shares with preferential rights for the Company's existing shareholders of up to DKK 51.2 million before transaction costs (the "Rights Issue"), which was resolved by the Board of Directors on 13 February 2024. The Information Memorandum is available on the Company's, Nordic Issuing AB's and Redeye AB's respective websites (www.curasight.com , www.nordic-issuing.se , www.redeye.se).
Summary of the Rights Issue
Each existing share in the Company, as of the record date on 22 February 2024, entitles the holder to one (1) subscription right. Seven (7) subscription rights entitle the holder to subscribe for one (1) new share at a subscription price of DKK 18 per share.
The subscription period runs from 23 February 2024, up to and including 7 March 2024.
The Company's management team, consisting of Ulrich Krasilnikoff (CEO and CFO), Andreas Kjær (CSO/CMO and co-founder) and Hanne Damgaard Jensen (CDO/COO), and members of the Company's Board of Directors, consisting of Per Falholt, Charlotte Vedel, and Kirsten Drejer, have committed to subscribe for shares in the rights issue for a total of approx. DKK 1.7 million, corresponding to 3.4 percent of the rights issue.
The proceeds are intended to be used to strengthen the Company's capital structure and secure funding for the acceleration of clinical activities, including the preparation, planning and enrolment of the first patients in a therapy phase I/IIa basket trial in various cancer types (brain, neuroendocrine, head and neck, non-small cell lung and pancreatic cancer), as well as to strength Curasight's pipeline through development of new peptide-based radioligand therapies.
Information Memorandum
Full terms and conditions for the Rights Issue as well as other information about the Company and further information about subscription commitments, is included in the Information Memorandum. The Information Memorandum is available on the Company's, Nordic Issuing AB's and Redeye AB's respective websites (www.curasight.com, www.nordic-issuing.se, www.redeye.se). Subscription forms will be available on the Company's, Nordic Issuing AB's, and Redeye AB's respective websites.
Timetable for the Rights Issue
21 February ? 5 March 2024
Trading in subscription rights
22 February 2024
Record date for the Rights Issue
22 February 2024
Publication of the Information Memorandum
23 February ? 7 March 2024
Subscription period
23 February until the Rights Issue is registered with the Danish Business Authority
Trading in temporary shares
Around 12 March 2024
Estimated publication of the outcome in the Rights Issue
Advisors
Redeye AB is acting as a financial advisor to Curasight. DLA Piper Denmark Advokatpartnerselskab is acting as the legal adviser of Curasight. VP Euronext Securities A/S is the Company's issuing agent and Nordic Issuing is acting as the settlement agent.
For more information regarding Curasight, please contact:
Methodist Le Bonheur Healthcare announced Methodist University Hospital earned top recognition by Money magazine as one of the Best U.S. Hospitals for Cardiac Care. The Memphis-based healthcare system's academic flagship landed 15th out of 75 and is...
Avicenna.AI, a leading medical imaging AI company, has received Medical Device Regulation (MDR) certificate for five of its algorithms from certification body BSI Medical Devices. This development means the company's product portfolio is fully...
Insmed Incorporated , a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that additional positive results from the ASPEN...
In March 2024, dairy cows in Texas were found to be infected with highly pathogenic avian flu, or H5N1 bird flu, in the first known case of the virus spreading to cattle. Since then, H5N1 has been found in about 200 animals?and 3 people?across 12...
Emmaus Life Sciences, Inc. , a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the year ended December 31, 2023....
Global health company The Cigna Group will release its second quarter 2024 financial results on Thursday, August 1, 2024, and will host a conference call the same day....